Scribe Therapeutics is a molecular engineering company focused on creating best-in-class in vivo therapies that permanently treat the underlying cause of disease. Scribe is overcoming the limitations of current genome editing technologies by developing custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine.
Employees: 11-50
Total raised: $100M
Founded date: 2017
Investors 3
| Date | Name | Website |
| - | Avoro Capi... | avorocapit... |
| - | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 31.03.2021 | Series B | $100M | - |
Mentions in press and media 11
| Date | Title | Description |
| 19.06.2026 | Scribe Therapeutics Awarded Over $25 Million From CIRM For CRISPR-Based Gene Editing Programs | Scribe Therapeutics announced that it has been awarded more than $25 million from the California Institute for Regenerative Medicine across two preclinical programs targeting cardiovascular and metabolic disease. The awards were made throug... |
| 01.04.2024 | Впервые в мире почку свиньи изменили генетически и пересадили человеку. Теперь их можно массово пересаживать... | Хирурги из США провели человеку трансплантацию почки, полученной из генетически модифицированной свиньи. СМИ сообщают, что данная операция является прорывом в области ксенотрансплантации, когда органы, клетки или ткани пересаживаются из одн... |
| 31.03.2021 | Scribe Therapeutics Raises $100M Series B Financing to Further Develop “CRISPR by Design” Platform and Pipeline of Breakthrough Genetic Medicines | - |
| 31.03.2021 | Scribe Therapeutics Scores $100M Series B | ALAMEDA, CA, Scribe Therapeutics has completed an oversubscribed $100M Series B financing led by Avoro Ventures and Avoro Capital Advisors. >> Click here for more funding data on Scribe Therapeutics >> To export Scribe Thera... |
| 31.03.2021 | Scribe Therapeutics snags $100M for engineered CRISPR tech, pipeline | Scribe Therapeutics is adding another $100 million to its coffers six months after unveiling a $20 million series A and a partnership with Biogen to work on gene editing treatments for amyotrophic lateral sclerosis (ALS). The new funds will... |
| 31.03.2021 | Scribe Therapeutics Raises $100M Series B Financing to Further Develop “CRISPR by Design” Platform and Pipeline of Breakthrough Genetic Medicines | Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced the completion of an oversubscribed $100M Series B financing. Avoro Ventures and Avoro Capi... |
| 07.10.2020 | Scribe Therapeutics Procures $20M in Series A | ALAMEDA, CA, Scribe Therapeutics procures $20M in Series A Funding led by Biogen. >> Click here for more funding data on Scribe Therapeutics >> To export Scribe Therapeutics funding data to PDF and Excel, click here Scrib... |
| 06.10.2020 | Scribe Therapeutics emerges with $20M, Biogen pact to clear CRISPR hurdles | CRISPR evolved in bacteria as a form of “genetic vandalism,” as George Church, Ph.D., puts it, to fend off pathogens. That means it works very well in bacteria but runs into various obstacles when researchers try to put it to work in humans... |
| 06.10.2020 | Scribe Therapeutics launches a platform for engineering CRISPR-based therapeutics | A new company called Scribe Therapeutics founded by two former members of CRISPR pioneer Jennifer Doudna’s UC Berkeley genetics lab (alongside Doudna herself) launched on Tuesday, debuting a platform designed specifically to help develop an... |
| - | Meet the 30 young leaders forging a new future for the healthcare industry in 2021 | From left: Dr. Isaac Kinde, Thrive's cofounder and head of research and innovation; Dr. Asima Ahmad, a cofounder and the chief medical officer of Carrot Fertility; Harpreet Singh Rai, the CEO of Oura; and Deena Shakir, a partner at Lux Capi... |
Show more